SUBSCRIBE
SUBSCRIBE
News   Policy

U.S. FDA Panel Rejects FDA and Genentech (South SF)'s (JOBS) Xolair Asthma Drug for Children

November 19, 2009 | 
1 min read
Bookmark and Share

Reuters -- Roche and Novartis's asthma drug Xolair should not be approved for children aged 6 to 11, a U.S. advisory panel decided on Wednesday.
Regulatory
Genentech, Inc. Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Illustration showing a downward graph trend
Regulatory
Future of Aardvark’s Prader-Willi drug in doubt as FDA slaps full hold on program
May 15, 2026
 · 
2 min read
 · 
Tristan Manalac
Businessperson group is walking towards career success or a vacant promotion competition. isometric vector illustration.
FDA
Biotech leaders pitch Pazdur as next FDA chief
May 14, 2026
 · 
2 min read
 · 
Annalee Armstrong
Editable vector illustration of a man winning a race. Hi-res jpeg file included.
Approvals
BeOne wins mantle cell lymphoma approval, opening new therapy class
May 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Businessman pulling rope trying to lift up falling graph.
Complete response letters
UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged
May 13, 2026
 · 
3 min read
 · 
Annalee Armstrong